Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a ...

SHR-1701 plus CAPOX chemotherapy reduced treatment delays and dose reductions compared with placebo plus CAPOX in HER2-negative gastric/GEJ cancer. The bifunctional PD-L1/TGF-β inhibitor SHR-1701, in ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized ...

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy. Five-year follow-up data from the phase 3 CheckMate 649 trial ...

22% of Community Providers Reported Biomarker Testing in Gastric/GEJ Cancers ...